Transport of μ-opioid receptor agonists and antagonist peptides across Caco-2 monolayer

Peptides

Volumn 29, Issue 6, 2008, Pages 1042-1047

  Iwan, Małgorzata ^a   Jarmołowska, Beata ^a   Bielikowicz, Krzysztof ^a   Kostyra, Elzbieta ^a   Kostyra, Henryk ^b   Kaczmarski, Maciej ^c  

^a UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^b INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Caco 2; Casomorphin; Opioid peptide; Peptide transport; Transepithelial transport

Indexed keywords

BETA CASOMORPHIN 7; BETA CASOMORPHINE 5; DIPEPTIDYL PEPTIDASE IV; LACTOFERROXIN A; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; BETA CASOMORPHINS; BETA-CASOMORPHIN 5; BETA-CASOMORPHINS; ENDORPHIN; LACTOFERRIN; LACTOFERRIN (318 323); LACTOFERRIN (318-323); MU OPIATE RECEPTOR; OLIGOPEPTIDE; PEPTIDE FRAGMENT;

ARTICLE; CELL STRAIN CACO 2; FOOD; HUMAN; HUMAN CELL; INTESTINE MUCOSA; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN TRANSPORT; CELL MEMBRANE PERMEABILITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENDOCYTOSIS; EPITHELIUM; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; ENDOCYTOSIS; ENDORPHINS; EPITHELIUM; HUMANS; INTESTINAL MUCOSA; LACTOFERRIN; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECEPTORS, OPIOID, MU;

EID: 43049162813     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.01.018     Document Type: Article

References (34)

1. Alfalah M., Jacob R., and Naim H.Y. Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains. J Biol Chem 277 March 22 (12) (2002) 10683-10690
2. Artursson P., and Borchardt R.T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharmaceut Res 14 12 (1997) 1655-1659
3. Artursson P., Palm K., and Luthmanb K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Del Rev 46 (2001) 27-43
4. Atisook K., and Madara J.L. An oligopeptide permeates intestinal tight junctions at glucose-elicited dilatations: implications for oligopeptide absorption. Gastroenterology 100 (1991) 719-724
5. Cieślińska A., Kamiński S., Kostyra E., and Sienkiewicz-Szłapka E. Beta-casomorphin 7 in raw and hydrolyzed milk derived from cows of alternative beta-casein genotypes. Milchwissenschaft 62 2 (2007) 125-127
6. Clare D.A., and Swaisgood H.E. Bioactive milk peptides: a prospectus. J Dairy Sci 83 (2000) 1187-1195
7. Darmoul D., Lacasaj M., Baricault L., Marguetll D., Sapin C., Trototj P., Barbat A., and Trugnan G. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. J Biol Chem 267 7 (1992) 4824-4833
8. Elitsur Y., and Luk G.D. Beta-casomorphin (BCM) and human colonic lamina propria lymphocyte proliferation. Clin Exp Immunol 85 (1991) 493-497
9. Ganapathy V., and Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS J 7 4 (2005) 852-885
10. Goody R., and Kitchen I. Influence of maternal milk on functional activation of d-opioid receptors in postnatal rats. JPET 296 (2001) 744-748
11. Jarmołowska B., Bielikowicz K., Iwan M., Sidor K., Kostyra E., and Kaczmarski M. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4. 14. 5) in breast-fed infants with symptoms of allergy. Peptides 28 (2007) 678-682
12. Jarmolowska B., Kostyra E., Krawczuk S., and Kostyra H. β-Casomorphin-7 isolated from Brie cheese. J Sci Food Agric 79 (1999) 1788-1792
13. Jarmołowska B., Sidor K., Iwan M., Bielikowicz K., Kaczmarski M., Kostyra E., and Kostyra H. Changes of b-casomorphin content in human milk during lactation. Peptides 28 (2007) 1982-1986
14. Knipp G.T., Vander Velde D.G., Siahaan T.J., and Borchardt R.T. The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cells monolayers. Pharmaceut Res 14 10 (1997) 1332-1341
15. Kostyra E., Sienkiewicz-Szłapka E., Jarmołowska B., Krawczuk S., and Kostyra H. Opioid peptides derived from milk proteins. Pol J Food Nutr Sci 13 54 (2004) 25-35
16. Lindström L.H., Nyberg F., Terenius L., Bauer K., Besev G., Gunne L.M., Lyrenäs S., Willdeck-Lund G., and Lindberg B. CSF and plasma beta-casomorphin-like opioid peptides in postpartum psychosis. Am J Psychiatry 141 9 (1984) 1059-1066
17. Pasi A., Mahler H., Lansel N., Bernasconi C., and Messiha F.S. Beta-Casomorphin-immunoreactivity in the brain stem of the human infants. Res Commun Chem Pathol Pharmacol 80 3 (1993) 305-322
18. Pauletti G.M., Gangwar S., Knipp G.T., Nerurkar M.M., Okumu F.W., Tamura K., et al. Structural requirements for intestinal absorption of peptide drugs. J Control Release 41 (1996) 3-17
19. Pauletti G.M., Okumu F.W., and Burchardt R.T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharmaceut Res 14 2 (1997) 164-169
20. Quan Y.-S., Fujita T., Tohara D., Tsuji M., Kohyama M., and Yamamoto A. Transport kinetics of leucine enkephalin across Caco-2 monolayers: quantitative analysis for contribution of enzymatic and transport barrier. Life Sci 64 14 (1999) 1243-1252
21. Reichelt K.L., and Knivsberg A.M. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides?. Nutr Neurosci 6 1 (2003) 19-28
22. Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., and Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21 (2005) 1-26
23. Shimidzu M., Tsunogai M., and Arai S. Transepithelial transport of oligopeptides in the human intestinal cell, caco-2. Peptides 5 (1997) 681-687
24. Tavelin S., Gråsjö J., Taipalensuu J., Ocklind G., and Artursson P. Applications of epithelial cell culture in studies of drug transport. In: Wise C. (Ed). Epithelial cell culture protocols (2002), Humana Press Inc, Totowa, NJ 233-272
25. Sternini C., Patierno S., Selmer S., and Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16 Suppl. 2 (2004) 3-16
26. Sturner R.A., and Chang J.K. Opioid peptide content in infant formulas. Pediatr Res 23 (1988) 4-10
27. Sun Z., Cade J.R., Fregly M.J., and Privette R.M. β-Casomorphin Induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism 3 1 (1999) 67-83
28. Sun Z., and Cade J.R. A peptide found in schizophrenia and autism causes behavioral changes in rats. Autism 3 1 (1999) 85-95
29. Sun Z., Zhang Z., Wang X., Cade R., and Elmir Z. Relation of β-casomorphins to apnea in sudden infant death syndrome. Peptides 24 (2003) 937-943
30. Svedberg J., de Haas J., Leimenstoll G., Paul F., and Teschemacher H. Demonstration of β-casomorphin immunoreactive materials in in vitro digests of bovine milk and in small intestine contents after bovine milk ingestion in adult humans. Peptides 6 (1985) 825-830
31. Teschemacher H. Opioid receptor ligands derived from food proteins. Curr Pharmaceut Des 9 (2003) 1331-1344
32. Watanabe Y., Kojima-komatsu T., Iwaki-egura, and Fujimoto Y. Increased excretion of proline-containing peptides in dipeptidyl peptidase IV deficient rats. Res Comm Clin Pathol Pharmacol 81 (1993) 323-330
33. Weaver L.T. Breast and gut: the relationship between lactating mammary function and neonatal gastrointestinal function. Proc Nutr Soc 51 (1992) 155-163
34. Yang C.Y., Dantzig A.H., and Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharmaceut Res 16 9 (1999) 1331-1342